Mediolanum International Funds Ltd Has $6.35 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Mediolanum International Funds Ltd raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 24,539 shares of the medical research company’s stock after acquiring an additional 1,989 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Amgen were worth $6,347,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Amgen during the second quarter worth approximately $16,515,000. Centaurus Financial Inc. boosted its holdings in shares of Amgen by 16.8% during the 2nd quarter. Centaurus Financial Inc. now owns 1,615 shares of the medical research company’s stock worth $505,000 after buying an additional 232 shares during the period. Neville Rodie & Shaw Inc. grew its stake in Amgen by 19.2% in the 3rd quarter. Neville Rodie & Shaw Inc. now owns 1,430 shares of the medical research company’s stock valued at $461,000 after buying an additional 230 shares during the last quarter. Park National Corp OH raised its holdings in Amgen by 2.6% in the 3rd quarter. Park National Corp OH now owns 2,210 shares of the medical research company’s stock worth $712,000 after acquiring an additional 55 shares during the period. Finally, AMF Tjanstepension AB lifted its position in Amgen by 16.9% during the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after acquiring an additional 17,387 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on AMGN shares. UBS Group lowered their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Truist Financial decreased their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Royal Bank of Canada restated an “outperform” rating and issued a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Redburn Partners decreased their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Sanford C. Bernstein initiated coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $314.00.

Amgen Stock Up 0.5 %

NASDAQ:AMGN opened at $285.42 on Friday. The company has a market cap of $153.42 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The stock’s fifty day moving average price is $271.24 and its two-hundred day moving average price is $304.84. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the business earned $4.96 earnings per share. On average, analysts anticipate that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.34%. Amgen’s payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.